Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM9Z4N5)

Drug Name
Zilucoplan Drug Info
Synonyms RA101495
Indication
Disease Entry ICD 11 Status REF
Generalized myasthenia gravis 8C60 Approved [1]
Myasthenia gravis 8C6Y Phase 3 [2]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [3]
Cross-matching ID
PubChem CID
133083018
CAS Number
CAS 1841136-73-9
TTD Drug ID
DM9Z4N5

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Generalized myasthenia gravis
ICD Disease Classification 8C60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216834
2 ClinicalTrials.gov (NCT04225871) Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT). U.S. National Institutes of Health.
3 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)